close

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements in the medical and veterinarian markets worldwide. Its products include Point-Of-Care Blood Chemistry Analyzer, which performs a panel of 14 tests on human patients and 13 tests on veterinary patients marketed under the Piccolo xpress and Piccolo Classic names in the human medical market and under the VetScan VS2 and VetScan Classic names in the veterinary market. The company's products also include Reagent Discs that handle various technical steps of blood chemistry testing automatically; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, which offer blood count analysis for veterinary applications. In addition, its products comprise VetScan VSpro that assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular disease, hepatic disease and monitoring therapy, and progression of disease states; and VetScan Canine Heartworm Rapid Test, a test for the detection of dirofilaria immitis in canine whole blood, serum, or plasma. Further, Abaxis's products consist of Orbos Discrete Lyophilization Process, which allows the production of active chemical ingredient in the form of a soluble bead, as well as involves in flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The company markets and sells its products through a direct sales force in the United States and through independent distributors. Abaxis was founded in 1989 and is headquartered in Union City, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	28.51
Volume	92020
Volume Avg	98658
52 Week High	31.69
52 Week Low	19.68
PE	53.38
PE (group average)	39
EPS Year	0.52
EPS change Q/Q	-11.76%
EPS change Q/Q Yr ago	25%
EPS change Q/Q next Q est	-11.76%
EPS change Y/Y	-7.69%
REV change Q/Q	4.46%
REV change Q/Q Yr ago	11.28%
EPS next Q est	0.17
EPS next Y est	0.82
Divident Annual	0.00
Dividend Yield	0%